AI Article Synopsis
- A study was conducted to assess the effectiveness and safety of lobeglitazone compared to sitagliptin when used alongside metformin in type 2 diabetes patients who weren’t adequately managed by metformin alone.
- The results showed that both medications had similar impacts on lowering HbA1c levels, with lobeglitazone showing a change of -0.79% and sitagliptin -0.86%, confirming their non-inferiority.
- Additionally, lobeglitazone demonstrated a greater reduction in metabolic syndrome components and favorable changes in lipid metabolism, while maintaining a safety profile similar to that of sitagliptin.
Article Abstract
We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%; P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.14085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!